贝组替凡联合卡博替尼一线治疗晚期透明细胞肾细胞癌(LITESPARK-003):开放标签、单臂、2期研究
LITESPARK-003是一项在美国十家医院开展的开放标签、单臂、2期研究,评估贝组替凡联合卡博替尼一线治疗晚期透明细胞肾细胞癌的疗效与安全性。50例患者中确认客观缓解率为70%(95%CI 55-82),含4例完全缓解;最常见3-4级治疗相关不良事件为高血压、贫血和疲乏。作者认为该方案具有前景,需进一步研究。
要点
- 贝组替凡120mg每日一次联合卡博替尼60mg每日一次一线治疗晚期透明细胞肾细胞癌。
- 确认客观缓解率70%(95%CI 55-82),其中完全缓解4例(8%)、部分缓解31例(62%)。
- 最常见3-4级治疗相关不良事件为高血压6例(12%)、贫血5例(10%)、疲乏4例(8%)。
核心结论
- 贝组替凡联合卡博替尼在初治晚期透明细胞肾细胞癌患者中显示出有前景的抗肿瘤活性,有必要进一步研究HIF-2α抑制剂联合多靶点酪氨酸激酶抑制剂作为该人群的治疗选择。
研究设计与样本
- LITESPARK-003为开放标签、单臂、2期研究,在美国十家医院和癌症中心开展。
- 队列1纳入至少18岁、ECOG体能状态0或1、未接受过晚期或转移性肾细胞癌全身治疗的患者。
- 患者接受贝组替凡120mg口服每日一次联合卡博替尼60mg口服每日一次,直至不可接受的不良事件、疾病进展或患者退出。
- 主要终点为研究者根据RECIST 1.1评估的确认客观缓解;抗肿瘤活性和安全性在所有接受至少一剂研究治疗的患者中评估。
主要发现
- 2018年9月27日至2023年1月10日筛查138例患者,50例(36%)入组队列1;中位年龄64岁(IQR 57-72),男性40例(80%)、女性10例(20%)。
- 截至数据截止日2023年5月15日,中位随访24.3个月(IQR 13.9-32.0)。
- 50例中35例(70%,95%CI 55-82)达到确认客观缓解,其中完全缓解4例(8%)、部分缓解31例(62%)。
- 最常见的3-4级治疗相关不良事件为高血压6例(12%)、贫血5例(10%)、疲乏4例(8%)。
- 50例中7例(14%)发生严重治疗相关不良事件;未发生治疗相关死亡。
关键数值与推荐
- 确认客观缓解率70%(95%CI 55-82),完全缓解率8%,部分缓解率62%。
- 3-4级治疗相关不良事件:高血压12%、贫血10%、疲乏8%。
- 严重治疗相关不良事件发生率14%,治疗相关死亡0例。
临床怎么用
- 作者认为贝组替凡联合卡博替尼在初治晚期透明细胞肾细胞癌中具有前景,有必要进一步研究HIF-2α抑制剂联合多靶点酪氨酸激酶抑制剂作为该人群的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial. METHODS: LITESPARK-003 is an open-label, single-arm, phase 2 study at ten hospitals and cancer centres in the USA. In cohort 1, eligible patients were at least 18 years of age, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had received no previous systemic therapy for locally advanced or metastatic renal cell carcinoma. Patients received belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily until unacceptable adverse events, disease progression, or patient withdrawal. The primary endpoint was investigator-assessed confirmed objective response according to Response Evaluation Criteria in Solid Tumors version 1.1. Antitumour activity and safety were assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03634540, and is ongoing. FINDINGS: Between Sept 27, 2018, and Jan 10, 2023, we screened 138 patients for eligibility, and 50 (36%) were enrolled and assigned to cohort 1. The median age was 64 years (IQR 57-72). 40 (80%) of 50 patients were male and ten (20%) were female. 48 (96%) patients were White, one (2%) patient was Black or African American, and one (2%) was of a race in the other category. As of the data cutoff (May 15, 2023), median follow-up was 24·3 months (IQR 13·9-32·0). 35 (70%, 95% CI 55-82) of 50 patients had a confirmed objective response, including four (8%) who had a complete response and 31 (62%) who had a partial response. The most frequent grade 3-4 treatment-related adverse events were hypertension (six [12%] patients), anaemia (five [10%] patients), and fatigue (four [8%] patients). Seven (14%) of 50 patients had serious treatment-related adverse events. No treatment-related deaths occurred. INTERPRETATION: Belzutifan plus cabozantinib has promising antitumour activity in treatment-naive patients with advanced clear-cell renal cell carcinoma and further investigation of an HIF-2α inhibitor in combination with a multitargeted tyrosine kinase inhibitor as a treatment option in this population is warranted. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA, and the National Cancer Institute.
引用
- Choueiri TK, Merchan JR, Figlin R, et al. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025. PMID: 39756444. doi:10.1016/S1470-2045(24)00649-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。